1Kalina A, Csaszer A, Fust G, et al. The association of serum lipoproteln(a) levels, apolipoprotein ( a ) size and (TTTTA) n polymorphismwith coronary heart disease[J]. Clin Chem Aeta, 2001, 309(1) :45--51.
2Gonbert S,Saint-Jore B,Giral P, et al. Molecular analysis of apo(a) fragmentation in polygenic hypercholesterolemia; characterization of a new plasma fragment pattern. Arterioscler Thromb Vase Biol,2001,21 (8) 1353-- 1358.
4Yazici M, Demircan S, Durna K, et al. Lipoprotein (a) levels in patients with unstable angina and their relationship with atherothrombosis and myocardial damage. Int J Clin Pract, 2005, 59 (2). 150--155.
5Billups KL. Erectile dysfunction as a marker for vascular disease. Curr Urol Rep. 2005, 6(6): 439--444.
6Furuya K, Zhu L, Kawahara N, et al. Differences in infarct evolution between lipopolysaccharide-induced tolerant and nontolerant conditions to focal cerebral ischemia. J Neurosurg, 2005, 103(4): 715--723.
7Devlin CM , Lee SJ. Kuriakose G, et al. An apolipoprotein(a) peptide, delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler. Thromb Yasc Biol. 2005, 25(8):1704--1710.
8Tsironis LD, Katsouras CS, Lourida ES, et al. Reduced PAF- acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 2004. 177 (1) . 193--201.
9Tsimikas S. Bri-lakis ES, Miller ER, McConnell JP, Lennon RJ, Konunan Ks, et al. Oxidized phospholipids. Lp (a) lipoprotein, and coronary artery dlsease(J)N Engl J Med. 2005, 353(1) : 46-- 57.
10Buechler C, Ullrich H, Ritter M, et al. Lipoprotein(a) up-regulares the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood, 2001, 97 (4) :981--986.
二级参考文献7
1Panizo A,Pardo J,Hemandez M,et al.Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats[J].Am Hypertens,1995,8:815.
2Deverux RB,Pickering TG,Alderman MH,et al.Left ventricular hypertrophy in hypertension prevalence and relationship to pathyphysiology[J].Hypertension,2000,9(Suppl):53.
3Diez J,Laviades C,et al.Increased serum concentrations of pracallagen peptides in essential hypertension relation to cardiac alterations[J].Circulations,2001,91:1450.
4Deverenux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am Cardiol,1986,57:450.
